Table 2. Observed responses.
| Patient | Best response | Prior nthracycline | Number of cycles received | Reason for discontinuation |
|---|---|---|---|---|
| 1 | PR | No | 6 | PD |
| 2 | SD | CAF | 6 | PD |
| 3 | Not evaluable1 | No | 1 | AE |
| 4 | PR | AC | 15 | PD |
| 6 | SD | No | 2 | AE |
| 7 | PR | AC | 12 | AE |
| 8 | SD | AC | 4 | PD |
| 9 | PR | AC | 16 | PD |
| 10 | SD | No | 4 | Patient wishes |
| 11 | PR | AC | 1 | AE |
1
Patient withdrew before day 15 of cycle 1
AC: doxorubicin and cyclophosphamide
CAF: cyclophosphamide, doxorubicin, and 5-fluorouracil
PR: partial response
SD: stable disease
PD: progressive disease
AE: adverse events